Despite the wide therapeutic arsenal of anti-seizure drugs available for the symptomatic treatment of epilepsy, more than 30% of patients continue to have seizures refractory to pharmacotherapy[1]. This drug resistance is associated with a mortality rate 2 to 3 times higher than the general population’s[2]. This excess mortality is linked to the direct consequences of the seizure (traumatic, drowning, inhalation, etc.), to the cause of epilepsy, status epilepticus and also to the increased risk of sudden and unexpected death (SUDEP)[2,3].
15
ENE
ENE
0